Affordable Access

deepdyve-link
Publisher Website

Proton Pump Inhibitors Independently Protect Against Early Allograft Injury or Chronic Rejection After Lung Transplantation.

Authors
  • Lo, Wai-Kit1, 2, 3
  • Goldberg, Hilary J3, 4
  • Boukedes, Steve4
  • Burakoff, Robert1, 3
  • Chan, Walter W5, 6
  • 1 Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
  • 2 Department of Gastroenterology, Boston VA Healthcare System, Boston, MA, USA.
  • 3 Harvard Medical School, Boston, MA, USA.
  • 4 Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • 5 Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. [email protected]
  • 6 Harvard Medical School, Boston, MA, USA. [email protected]
Type
Published Article
Journal
Digestive Diseases and Sciences
Publisher
Springer-Verlag
Publication Date
Feb 01, 2018
Volume
63
Issue
2
Pages
403–410
Identifiers
DOI: 10.1007/s10620-017-4827-0
PMID: 29094310
Source
Medline
Keywords
License
Unknown

Abstract

Post-lung transplant exposure to persistent PPI therapy results in the greatest protection against rejection in lung transplant recipients, independent of other clinical predictors including BMI, suggesting that PPI may have antireflux or anti-inflammatory effects in enhancing allograft protection.

Report this publication

Statistics

Seen <100 times